Description
ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1) is a cell surface protein that serves as a therapeutic target in cancer treatment. ROR1-targeted therapies are designed to bind to this receptor, which is overexpressed in various cancer cells including some colorectal tumors.
Mechanism of Action
ROR1-targeted agents work by binding to the ROR1 receptor on cancer cell surfaces, leading to targeted cell death through immune-mediated mechanisms or direct cytotoxic effects. This approach selectively targets cancer cells while sparing normal tissues that typically express low levels of ROR1.
Side Effects
Infusion reactions
Fatigue
Nausea
Diarrhea
Decreased appetite
Skin rash
Potential cytopenias
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04842812
med_phase_prefix1
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
China